U.S. markets close in 3 hours 29 minutes

Amneal Pharmaceuticals, Inc. (AMRX)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
4.0850+0.0450 (+1.11%)
As of 12:30PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close4.0400
Open4.0700
Bid4.0500 x 1300
Ask4.0600 x 800
Day's Range3.9700 - 4.1000
52 Week Range2.4000 - 5.7900
Volume320,952
Avg. Volume1,179,946
Market Cap603.06M
Beta (5Y Monthly)1.26
PE Ratio (TTM)9.77
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    5 Value Stocks To Watch In The Healthcare Sector

    Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.The following stocks are considered to be notable value stocks in the healthcare sector: 1. Satsuma Pharmaceuticals (NASDAQ: STSA) - P/E: 2.34 2. Acorda Therapeutics (NASDAQ: ACOR) - P/E: 0.69 3. Biogen (NASDAQ: BIIB) - P/E: 8.05 4. Amneal Pharmaceuticals (NYSE: AMRX) - P/E: 9.13 5. Bio-Rad Laboratories (NYSE: BIO) - P/E: 4.88This quarter, Satsuma Pharmaceuticals experienced a decrease in earnings per share, which was -0.65 in Q2 and is now -0.69. Satsuma Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Acorda Therapeutics reported earnings per share at -0.23, whereas in Q2 earnings per share sat at -0.35. Acorda Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Biogen's earnings per share for Q3 sits at 8.84, whereas in Q2, they were at 10.26. Biogen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Amneal Pharmaceuticals reported earnings per share at 0.16, whereas in Q2 earnings per share sat at 0.13. Amneal Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.This quarter, Bio-Rad Laboratories experienced an increase in earnings per share, which was 1.61 in Q2 and is now 3.0. Bio-Rad Laboratories does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.See more from Benzinga * Click here for options trades from Benzinga * Overview Of Value Stocks In The Real Estate Sector * A Preview Of Dick's Sporting Goods's Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Is Amneal Pharmaceuticals (AMRX)  a Good Stock to Pick Now?
    Zacks

    Is Amneal Pharmaceuticals (AMRX) a Good Stock to Pick Now?

    Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.

  • The Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
    Simply Wall St.

    The Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

    Last week, you might have seen that Amneal Pharmaceuticals, Inc. (NYSE:AMRX) released its third-quarter result to the...